# HARMONi-3: HCP commentary report

> 286 verified statements (114 from clinicians verified by NPI or staff page) from 97 commentary sources · 11 findings · commentary checked Nov 4, 2026

## Report

- Trial: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
- NCT ID: NCT05899608
- Registry: https://clinicaltrials.gov/study/NCT05899608
- Sponsor: Summit Therapeutics
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: ivonescimab
- Indication: first-line metastatic non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-04 UTC
- Last checked: 2026-11-04 UTC
- Release hash: ac832e38b51895a7c2bdb453096f84e9ae6273eb29e4ad307428ab868692f383

## Counts

- Commentary sources screened: 142
- Sources cited by verified statements: 98
- Verified statements: 286
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 114
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 43
- Voices cited: 41
- Cited voices with a verified identity: 27
- Cited clinicians, voices with a confirmed clinical role (the abstract's clinicians): 21
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 20
- By role and specialty (the abstract's specialty counts):
  - 13 physician, Medical oncology
  - 6 physician
  - 1 pharmacist
  - 1 physician, Hematology and oncology
- Organisational or shared accounts (not counted as people): 21

A verified identity says who a voice is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified voices without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

HARMONi-3 compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer; the discussion weighs regional benefit signals against the need for global confirmation before changing practice. The report cites 20 physicians, including 13 medical oncologists, and one pharmacist. Further questions concern selection-dependent bleeding risk in squamous disease and whether histology or PD-L1 predicts benefit. What survival benefit worldwide, for which patients and with what harm linked to patient selection, would justify replacing pembrolizumab plus chemotherapy?

## Open Medical Affairs question

What global survival benefit, in which patients and with what selection-dependent harm, would justify replacing the current first-line backbone?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Clinicians welcome regional efficacy signals but still await global evidence before changing routine practice
- F2. Clinicians find squamous-disease safety reassuring with careful selection, not evidence of zero bleeding risk
- F3. Clinicians disagree over how much Chinese efficacy should be discounted before global confirmation
- F4. One pharmacist reads the interim update as inconclusive but concerning; other commentators differ over what it implies
- F5. Clinicians prioritize survival, while two clinicians differ over possible EU approval before global results
- F6. One pharmacist defends the chemotherapy control while asking whether bispecific linkage adds synergy
- F7. Episode commentary favors chemotherapy for most PD-L1-low patients and gives explicit reasons to omit it
- F8. One clinician calls NGS essential regardless of histology or tobacco exposure
- F9. Whether histology or PD-L1 predicts the benefit HARMONi-3 will show
- F10. Speakers see competing first-line strategies, but their views do not establish a head-to-head winner
- F11. One account sees histology separation as potential de-risking and asks what motivated it

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 21 | 18 | 8 | 7 | recorded | 3 |
| F2 | 16 | 16 | 10 | 12 | recorded | 3 |
| F3 | 12 | 12 | 6 | 7 | recorded | 3 |
| F4 | 20 | 12 | 7 | 7 | recorded | 3 |
| F5 | 15 | 16 | 11 | 9 | recorded | 3 |
| F6 | 12 | 7 | 6 | 6 | recorded | 3 |
| F7 | 12 | 9 | 6 | 5 | recorded | 3 |
| F8 | 2 | 2 | 1 | 1 | none recorded | 2 |
| F9 | 12 | 13 | 9 | 8 | recorded | 3 |
| F10 | 10 | 9 | 4 | 5 | recorded | 3 |
| F11 | 17 | 13 | 13 | 11 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 17 | 4 | 0 | 0 | 0 | 22 | 5 | 3 posts and articles, 5 podcasts and video | yes |
| F2 | 12 | 1 | 0 | 2 | 1 | 18 | 1 | 7 posts and articles, 3 podcasts and video | yes |
| F3 | 8 | 3 | 0 | 0 | 1 | 13 | 1 | 4 posts and articles, 2 podcasts and video | yes |
| F4 | 11 | 5 | 0 | 0 | 4 | 20 | 3 | 7 posts and articles | yes |
| F5 | 11 | 3 | 0 | 1 | 0 | 17 | 0 | 10 posts and articles, 1 podcast or video | yes |
| F6 | 7 | 2 | 0 | 3 | 0 | 12 | 0 | 4 posts and articles, 2 podcasts and video | yes |
| F7 | 5 | 1 | 2 | 1 | 3 | 13 | 3 | 4 posts and articles, 2 podcasts and video | yes |
| F8 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 1 podcast or video | yes |
| F9 | 8 | 2 | 0 | 1 | 1 | 12 | 1 | 8 posts and articles, 1 podcast or video | yes |
| F10 | 3 | 1 | 0 | 5 | 1 | 10 | 0 | 3 posts and articles, 1 podcast or video | yes |
| F11 | 6 | 3 | 0 | 0 | 8 | 17 | 0 | 12 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F1 (7 shared claims), F4 (2 shared claims), F5 (7 shared claims), F7 (2 shared claims), F9 (4 shared claims), F11 (2 shared claims)
- Primary endpoint: Progression Free Survival (PFS): F1 (2 shared claims), F2 (1 shared claims), F4 (19 shared claims), F5 (1 shared claims), F9 (3 shared claims), F11 (2 shared claims)
- Secondary endpoint: Adverse Event (AE): F2 (12 shared claims), F9 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (2 shared claims), F3 (10 shared claims), F7 (6 shared claims), F8 (2 shared claims), F9 (7 shared claims), F10 (1 shared claims), F11 (1 shared claims)
- The comparison: F1 (7 shared claims), F5 (1 shared claims), F6 (11 shared claims), F7 (3 shared claims), F9 (1 shared claims), F11 (1 shared claims)
- Safety and tolerability: F2 (16 shared claims), F3 (3 shared claims), F5 (1 shared claims), F9 (1 shared claims)
- Design and conduct: F4 (4 shared claims), F5 (1 shared claims), F11 (15 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- AE: adverse event
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NGS: next-generation sequencing
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- OS: overall survival
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival

## Sample findings

Paraphrased; the full report links each statement to its source.

### F6. One pharmacist defends the chemotherapy control while asking whether bispecific linkage adds synergy

A pharmacist's LinkedIn post raises questions about adding bevacizumab to the comparator and whether linking antibody targets creates synergy.

Source: LinkedIn post, 2025-04-22.

### F11. One account sees histology separation as potential de-risking and asks what motivated it

An X thread asks why HARMONi-3 adopted histology-specific analyses and whether signals from other studies informed that decision.

Source: X thread, 2025-10-20.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 286 | Paid |
| Who said each statement, with each cited voice's role and what confirmed it (NPI registry or staff page) | 41 | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 98 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 27 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 21 of the 41 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 47 | 28 |
| Primary endpoint: Progression Free Survival (PFS) | discussed | 38 | 21 |
| Secondary endpoint: Adverse Event (AE) | discussed | 22 | 10 |
| Population and setting | discussed | 37 | 21 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 36 | 18 |
| Safety and tolerability | discussed | 28 | 15 |
| Design and conduct | discussed | 28 | 19 |
| Global transferability, age and representativeness | discussed | 34 | 24 |
| Bispecific rationale and the incremental contribution of VEGF blockade | discussed | 17 | 15 |
| PD-L1-guided treatment choice and reasons to omit chemotherapy | discussed | 37 | 18 |
| Molecular work-up before systemic treatment selection | discussed | 2 | 1 |
| Competing ADC-based first-line strategies | discussed | 13 | 4 |
| Clinical adoption and regulatory evidentiary thresholds | discussed | 45 | 22 |
| Local research access and anticipation | discussed | 16 | 13 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 131 | 88 |
| LinkedIn posts | 3 | 3 |
| Podcasts | 3 | 3 |
| YouTube | 3 | 3 |
| Bluesky threads | 2 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-05-03 to 2026-10-28
- Cited window: 2023-10-14 to 2026-10-28
- Retrieved: 2026-11-04

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
- Registry: NCT05899608 (https://clinicaltrials.gov/study/NCT05899608)
- Study IDs: SMT112-3003
- Sponsor: Summit Therapeutics
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 1,600 (estimated)
- Start: 2023-10-26 (actual)
- Primary completion: 2028-12-31 (estimated)
- Primary endpoint: Overall Survival (OS) (approximately 4 years)
- Primary endpoint: Progression Free Survival (PFS) (approximately 3 years)
- Intervention: Ivonescimab Injection (biological)
- Intervention: Pembrolizumab Injection (biological)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on global applicability, patient selection and VEGF-related toxicity in first-line ivonescimab-based treatment.
- Not yet captured in this edition: a view on immunotherapy plus an ADC as an emerging first-line NSCLC treatment alternative.
- Not yet captured in this edition: a view on immunotherapy plus an ADC as an emerging first-line treatment alternative in non-small cell lung cancer.
- 1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 131 passages in 90 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 67 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 70 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selected collection, not a representative sample of HCP opinion. Repeated posts, relays and overlapping recordings do not establish additional independent speakers or consensus.
- Some potentially relevant passages were not fully assessed. Discussions that did not use recognizable trial names or that were transcribed differently may be missing, so the report cannot claim exhaustive coverage.
- Several passages, particularly on the September 2024 episode and in a short recap video, cannot be assigned to named speakers. They may belong to participants already discussed and are not counted as separate people.
- The material mixes clinical discussion with author, organization and investment-account commentary. A verified identity, a source-described credential or a dated affiliation does not establish expertise, independence or the truth of a view.
- No exact HARMONi-3 results publication, complete protocol or statistical plan, or exact regulatory label was available. Interim thresholds, modeled success probabilities, approval expectations and historical amendments are therefore reported at the level the sources support.
- Findings from HARMONi-2, HARMONi-6 and other studies are context for the first-line treatment question, not HARMONi-3 results. Cross-trial estimates, subgroup interpretations and different hemorrhage definitions cannot be combined into a single comparative conclusion.
- Dates attached to posts or published recordings do not necessarily date the underlying session or readout. Different timing statements are kept as contemporaneous expectations, not interpreted as demonstrated changes of mind.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-04 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-04 UTC. No changes.

## Offer

- Size: Standard · 286 verified statements · 114 from 21 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, never for outreach or targeting, at $15 per identity-verified person in the edition at purchase (27 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/harmoni-3-nct05899608
- Agents: POST https://www.erudio.com/api/orders with {"report": "harmoni-3-nct05899608", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=harmoni-3-05899608

## Cite

Erudio Health. HARMONi-3 (NCT05899608): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 4, 2026. https://www.erudio.com/reports/harmoni-3-nct05899608

## Machine access

- JSON: https://www.erudio.com/reports/harmoni-3-nct05899608.json
- Markdown: https://www.erudio.com/reports/harmoni-3-nct05899608.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/harmoni-3-nct05899608/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "harmoni-3-nct05899608"}`